Baojun Wang, Bo Jiang, Lin Du, Wenyuan Chen, Qing Zhang, Wei Chen, Meng Ding, Wenmin Cao, Jie Gao, Yongming Deng, Yao Fu, Yan Li, Yonglong Xiao, Wenli Diao, Hongqian Guo
{"title":"肿瘤固有RGS1通过ATF3-IFNGR1轴增强检查点阻断反应","authors":"Baojun Wang, Bo Jiang, Lin Du, Wenyuan Chen, Qing Zhang, Wei Chen, Meng Ding, Wenmin Cao, Jie Gao, Yongming Deng, Yao Fu, Yan Li, Yonglong Xiao, Wenli Diao, Hongqian Guo","doi":"10.1080/2162402x.2023.2279800","DOIUrl":null,"url":null,"abstract":"Non-responsiveness is a major barrier in current cancer immune checkpoint blockade therapies, and the mechanism has not been elucidated yet. Therefore, it is necessary to discover the mechanism and...","PeriodicalId":19683,"journal":{"name":"Oncoimmunology","volume":null,"pages":null},"PeriodicalIF":7.2000,"publicationDate":"2023-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tumor-intrinsic RGS1 potentiates checkpoint blockade response via ATF3-IFNGR1 axis\",\"authors\":\"Baojun Wang, Bo Jiang, Lin Du, Wenyuan Chen, Qing Zhang, Wei Chen, Meng Ding, Wenmin Cao, Jie Gao, Yongming Deng, Yao Fu, Yan Li, Yonglong Xiao, Wenli Diao, Hongqian Guo\",\"doi\":\"10.1080/2162402x.2023.2279800\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Non-responsiveness is a major barrier in current cancer immune checkpoint blockade therapies, and the mechanism has not been elucidated yet. Therefore, it is necessary to discover the mechanism and...\",\"PeriodicalId\":19683,\"journal\":{\"name\":\"Oncoimmunology\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":7.2000,\"publicationDate\":\"2023-11-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Oncoimmunology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/2162402x.2023.2279800\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Oncoimmunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/2162402x.2023.2279800","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Tumor-intrinsic RGS1 potentiates checkpoint blockade response via ATF3-IFNGR1 axis
Non-responsiveness is a major barrier in current cancer immune checkpoint blockade therapies, and the mechanism has not been elucidated yet. Therefore, it is necessary to discover the mechanism and...
期刊介绍:
Tumor immunology explores the natural and therapy-induced recognition of cancers, along with the complex interplay between oncogenesis, inflammation, and immunosurveillance. In response to recent advancements, a new journal, OncoImmunology, is being launched to specifically address tumor immunology. The field has seen significant progress with the clinical demonstration and FDA approval of anticancer immunotherapies. There's also growing evidence suggesting that many current chemotherapeutic agents rely on immune effectors for their efficacy.
While oncologists have historically utilized chemotherapeutic and radiotherapeutic regimens successfully, they may have unwittingly leveraged the immune system's ability to recognize tumor-specific antigens and control cancer growth. Consequently, immunological biomarkers are increasingly crucial for cancer prognosis and predicting chemotherapy efficacy. There's strong support for combining conventional anticancer therapies with immunotherapies. OncoImmunology will welcome high-profile submissions spanning fundamental, translational, and clinical aspects of tumor immunology, including solid and hematological cancers, inflammation, and both innate and acquired immune responses.